FDA Has Not Confirmed Suspension of Fast-Track Voucher Program Amid Record of 7 Approvals
Key Facts
A suspension of the U.S. Food and Drug Administration’s National Priority Voucher program could not be verified on the date of the report, as the linked report page in the news feed was unavailable. The agency’s program page says the pilot is exploring a pathway to shorten review times for drug and biologics applications, along with certain manufacturing or efficacy supplements. The pathway targets review within one to two months, compared with six months or more under other priority review programs. The agency says selected applications remain subject to the same statutory and regulatory approval requirements that apply to other applications. It therefore cannot be confirmed that the program was suspended or that the review pathway changed during the session covered by the report.
The FDA page indicates that the program had recorded its seventh approval as of May 8, 2026. An earlier agency update, dated March 20, 2026, said vouchers had been awarded to 18 products and that the program had resulted in four approvals at that point. Those results included two oncology drug approvals 44 and 55 days after the applications were submitted, according to the agency’s statement. These figures put the targeted review timeline in the context of the program’s implementation, but do not by themselves establish its status on the date of the report. The program page update also records approval of an immunotherapy for rectal cancer on October 19, 2026, a later approval listed in the initiative’s record.
According to the FDA’s questions and answers about the program, the agency is primarily focused on implementing the pilot but continues to accept expressions of interest and may award additional vouchers under its published eligibility criteria. This statement distinguishes continued acceptance of interest from awarding new vouchers, linking any additional awards to the specified criteria. Vouchers are also nontransferable, according to the program page, meaning the benefit awarded cannot be transferred to another party. Final approval decisions remain with the relevant product center, using its usual procedures. Regulatory approval therefore remains subject to the center’s decision and requirements, even when an application is included in the faster pilot pathway.
Rep. Jake Auchincloss raised concerns in February 2026 about the program’s transparency and legal basis, saying the FDA had not responded to congressional inquiries. The Associated Press reported that the lawmaker’s letter addressed the agency’s failure to publish or make available financial disclosure forms for eight senior officials who vote on which drugs are selected for vouchers. The criticism is part of the debate over how program recipients are chosen, but it does not confirm that the initiative has been suspended or explain a decision of that kind. In a separate statement, the agency said it was focused on implementation while continuing to accept expressions of interest, which remains its published description of the pilot’s status. Any subsequent change in accepting applications or awarding vouchers depends on an official agency update; the available information does not include a specific date for such an announcement.